By Counterforce Health Team in Xenpozyme (olipudase alfa-rpcp) —

How to Get Xenpozyme (olipudase alfa-rpcp) Covered by Aetna CVS Health in Washington: Complete Timeline and Appeals Guide

Answer Box: Getting Xenpozyme Covered by Aetna CVS Health in Washington

Timeline: 5-14 business days for standard prior authorization, 72 hours for expedited review. Requirements: Confirmed ASMD diagnosis with genetic testing (SMPD1 mutations) and enzyme activity <10% of normal, prescribed by metabolic specialist. First step: Have your doctor submit prior authorization through CVS Caremark at 1-888-267-3277 with complete genetic testing results and baseline organ assessments. If denied, Washington's external review process overturns ~82% of specialty drug denials.

Table of Contents

  1. What Affects Approval Timeline
  2. Pre-Submission Preparation (0-2 Days)
  3. Submission to Initial Review (1-5 Days)
  4. Additional Information Requests (1-7 Days)
  5. Decision Window & Outcomes
  6. If Your Request Is Denied
  7. Renewal and Reauthorization
  8. Coverage Requirements at a Glance
  9. Appeals Playbook for Washington
  10. Common Denial Reasons & Solutions
  11. FAQ

What Affects Approval Timeline

Several factors influence how quickly Aetna CVS Health processes your Xenpozyme prior authorization in Washington:

Benefit Type: Specialty medications like Xenpozyme are handled through CVS Caremark's specialty pharmacy division, which typically takes longer than standard drug reviews but follows more predictable timelines.

Documentation Completeness: The most common delays occur when genetic testing results are incomplete or baseline organ assessments are missing. Aetna requires both SMPD1 gene variants and enzyme activity levels documented before review begins.

Prescriber Qualifications: Aetna requires prescription by or consultation with a metabolic disease specialist or geneticist. If your primary care doctor submits without specialist involvement, expect delays for additional documentation.

Site of Care Considerations: During dose escalation, Xenpozyme must be administered in supervised clinical settings. Home infusion is only permitted during maintenance phase for stable patients, which affects coverage approval complexity.

Pre-Submission Preparation (0-2 Days)

Essential Documentation Checklist

Before submitting to Aetna CVS Health, gather these required documents:

Diagnostic Confirmation:

  • SMPD1 genetic testing showing two pathogenic variants
  • ASM enzyme activity results (<10% of normal)
  • ICD-10 diagnosis codes for ASMD (E75.240-E75.249)

Clinical Documentation:

  • Baseline liver enzymes (ALT/AST) within 1 month
  • Complete blood count with platelets
  • Spleen size assessment (imaging or physical exam)
  • Pulmonary function tests if respiratory symptoms present

Prescriber Information:

  • Board certification in genetics, metabolism, hematology, or related specialty
  • Medical necessity letter with treatment rationale
  • Prior treatment history and failures
Tip: Contact Sanofi's Xenpozyme support program for assistance with documentation templates and prior authorization support.

Submission to Initial Review (1-5 Days)

How to Submit

For specialty drugs like Xenpozyme:

Washington State Requirements: Aetna must acknowledge receipt within 1 business day and provide initial determination within the standard review timeline unless expedited review is requested.

What Reviewers Check First

  1. Diagnosis Confirmation: Verified ASMD with genetic and enzyme testing
  2. Prescriber Credentials: Specialist involvement documented
  3. Medical Necessity: Clear rationale for enzyme replacement therapy
  4. Site of Care Appropriateness: Escalation phase in clinical setting, maintenance potentially at home

Additional Information Requests (1-7 Days)

If Aetna requests additional information, respond within 14 days to avoid automatic denial. Common requests include:

  • Missing genetic testing results: Provide complete SMPD1 sequencing report
  • Baseline assessments: Submit all required organ function studies
  • Specialist consultation: Documentation of metabolic specialist involvement
  • Prior therapy documentation: Evidence of supportive care measures attempted
Note: Counterforce Health helps patients and clinicians prepare comprehensive appeals by analyzing denial letters and identifying specific evidence gaps that caused the initial rejection.

Decision Window & Outcomes

Standard Timeline

  • Initial review: 5-14 business days from complete submission
  • Expedited review: 72 hours with documented medical urgency
  • Complex cases: Up to 30 days with notification

Typical Outcomes

Approval: Initial authorization typically covers 6 months with specific site-of-care requirements during dose escalation.

Partial Approval: May approve with restrictions (specific infusion center, additional monitoring requirements).

Denial: Most common reasons include incomplete genetic testing, lack of specialist involvement, or site-of-care concerns.

If Your Request Is Denied

Don't give up—Washington has strong appeal rights, and specialty drug denials are frequently overturned.

Internal Appeals Process

First-Level Appeal:

  • Submit within 60 days of denial notice
  • Include additional clinical documentation
  • Request peer-to-peer review with Aetna medical director

Second-Level Appeal:

  • Available if first appeal denied
  • Independent medical review within Aetna
  • Final internal decision before external review

Expedited Appeals

If your condition is urgent, request expedited appeal with physician attestation that delay could seriously jeopardize your health.

Renewal and Reauthorization

Reauthorization Requirements

Initial approval: 6 months during dose escalation phase Maintenance approval: 12 months once stable dosing achieved

Required documentation for renewal:

  • Provider attestation of clinical response
  • Updated organ assessments (spleen volume, liver function, pulmonary tests)
  • Documentation of treatment tolerance
  • Continued specialist oversight

Timeline for Renewal Submission

Submit reauthorization requests 30-60 days before current approval expires to ensure continuous coverage.

Coverage Requirements at a Glance

Requirement Details Documentation Needed
Prior Authorization Required for all requests CVS Caremark PA form
Genetic Testing Two pathogenic SMPD1 variants Complete genetic sequencing report
Enzyme Activity <10% of normal ASM activity Laboratory enzyme assay results
Prescriber Metabolic specialist or geneticist Board certification documentation
Baseline Studies Organ function assessments Labs, imaging, pulmonary function
Site of Care Clinical setting during escalation Treatment plan with facility details
Appeals Deadline 60 days internal, 180 days external Washington state timeline

Appeals Playbook for Washington

Internal Appeals

  1. Submit written appeal within 60 days to Aetna member services
  2. Include new evidence addressing denial reasons
  3. Request peer-to-peer review between prescriber and Aetna medical director
  4. Timeline: 30 days for standard, 72 hours for expedited

External Review Process

Washington's external review process provides independent medical review:

Filing Requirements:

  • Submit within 180 days of final internal denial
  • Complete external review request form
  • Include all relevant medical records

Timeline:

  • Standard review: 30-45 days
  • Expedited review: 72 hours for urgent cases
  • Success rate: ~82% of specialty drug denials overturned

Contact Information:

Common Denial Reasons & Solutions

Denial Reason Solution Strategy
Incomplete genetic testing Submit complete SMPD1 sequencing with both variants identified
Lack of specialist involvement Obtain consultation note from metabolic disease specialist
Insufficient baseline data Complete all required organ assessments before resubmission
Site of care concerns Clarify escalation phase at clinical facility, maintenance at approved site
Medical necessity unclear Provide detailed treatment rationale with guideline references
Step therapy requirement Document contraindications or failures of alternative treatments
From our advocates: We've seen cases where initial denials for incomplete genetic testing were quickly overturned once families provided the complete SMPD1 sequencing report showing both pathogenic variants. The key is understanding exactly what documentation Aetna needs and providing it comprehensively the first time.

FAQ

Q: How long does Aetna CVS Health prior authorization take for Xenpozyme in Washington? A: Standard review takes 5-14 business days from complete submission. Expedited review with documented urgency takes 72 hours.

Q: What if Xenpozyme is not on Aetna's formulary? A: You can request a formulary exception with medical necessity documentation. If approved, you typically pay Tier 4 cost-sharing.

Q: Can I appeal if my doctor isn't a specialist? A: Yes, but you'll need consultation with a metabolic disease specialist or geneticist. This is a firm Aetna requirement for ASMD treatments.

Q: Does Washington's external review apply to employer plans? A: Most employer plans in Washington voluntarily use external review. Self-funded ERISA plans may have different procedures—contact the U.S. Department of Labor for ERISA appeals.

Q: What's the success rate for Xenpozyme appeals in Washington? A: External reviews overturn approximately 82% of specialty drug denials in Washington, indicating strong success rates for well-documented appeals.

Q: Can I get home infusion during dose escalation? A: No. Xenpozyme must be administered in a clinical setting during dose escalation due to infusion reaction risks. Home infusion is only permitted during stable maintenance dosing.

Q: What if I miss the appeal deadline? A: Contact the Washington Office of Insurance Commissioner immediately. In some cases, good cause exceptions may apply, especially if you didn't receive proper notice of appeal rights.

Q: How much does Xenpozyme cost without insurance? A: Wholesale acquisition cost ranges from $1,515 per 4mg vial to $7,576 per 20mg vial. Sanofi offers patient assistance programs for eligible patients.

Getting comprehensive support for your Xenpozyme appeal: Counterforce Health specializes in turning insurance denials into successful appeals by analyzing denial letters, identifying missing evidence, and crafting targeted rebuttals that address payers' specific concerns. Their platform helps patients, clinicians, and specialty pharmacies navigate complex prior authorization requirements and appeal processes for rare disease medications.

Sources & Further Reading

Disclaimer: This information is for educational purposes only and does not constitute medical or legal advice. Insurance coverage decisions depend on individual circumstances and plan details. Always consult with your healthcare provider and insurance company for guidance specific to your situation. For additional assistance with insurance appeals in Washington, contact the Office of the Insurance Commissioner at 1-800-562-6900.

Powered by Counterforce Health—AI that turns drug denials into evidence-based appeals patients and clinicians can submit today.